Literature DB >> 21712135

Comparison of CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae isolates from patients with bacteremia.

Juyoun Shin1, Dae Hun Kim, Kwan Soo Ko.   

Abstract

OBJECTIVE: Recently, CTX-M-15-producing Enterobacteriaceae has disseminated worldwide. To better understand the success of CTX-M-15-type extended-spectrum β-lactamase, we compared the CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae isolates with CTX-M-14-producing E. coli and K. pneumoniae isolates that had been more prevalent before the recent increase of CTX-M-15 in Korea.
METHODS: Eighty-nine CTX-M-producing E. coli bloodstream infection isolates and 33 K. pneumoniae bloodstream infection isolates were collected in 2008 from nine hospitals in Korea. In vitro susceptibility testing and multilocus sequence typing were performed for all isolates. Phylogenetic groupings and distribution of virulence determinants and addiction systems were examined for only E. coli isolates.
RESULTS: Among the 89 CTX-M-producing E. coli isolates, 54 isolates (60.7%) contained bla(CTx-M-15) and bla(CTx-M-14) was identified in 31 isolates (34.8%). Among 33 CTX-M-producing K. pneumoniae isolates, bla(CTx-M-14) and bla(CTx-M-15) were identified in 18 (54.5%) and 15 (45.5%) isolates, respectively. While CTX-M-14- and CTX-M-15-producing E. coli isolates displayed similar antimicrobial resistance rates, CTX-M-15-producing K. pneumoniae isolates showed significantly higher resistance rates of ciprofloxacin and piperacillin-tazobactam than CTX-M-14-producing isolates. ST131 and ST405 were the main clones in both CTX-M-14- and CTX-M-15-producing E. coli isolates. Although the frequency of virulence determinants was similar between two E. coli groups, ST131 and ST405 isolates producing CTX-M-15 showed higher frequency of determinants. In addition, CTX-M-15-producing E. coli isolates showed higher prevalence of addiction systems, particularly vagCD. ST405 showed the highest prevalence rates among main E. coli clones. In K. pneumoniae, ST15 and ST11, with high resistance rates, were the main clones of CTX-M-15-producing isolates, but no main clones was found among CTX-M-14-producing isolates because of extreme diversity.
CONCLUSIONS: Rapid increase of CTX-M-15-producing E. coli isolates was due to certain clone with high frequency of virulence determinants and addiction systems. High antimicrobial resistance rates of CTX-M-15-producing K. pneumoniae isolates may contribute to their increase.
Copyright © 2011 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21712135     DOI: 10.1016/j.jinf.2011.05.003

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  18 in total

1.  Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.

Authors:  Amee R Manges; Hyun Min Geum; Alice Guo; Thaddeus J Edens; Chad D Fibke; Johann D D Pitout
Journal:  Clin Microbiol Rev       Date:  2019-06-12       Impact factor: 26.132

2.  Association of fluoroquinolone resistance, virulence genes, and IncF plasmids with extended-spectrum-β-lactamase-producing Escherichia coli sequence type 131 (ST131) and ST405 clonal groups.

Authors:  Yasufumi Matsumura; Masaki Yamamoto; Miki Nagao; Yutaka Ito; Shunji Takakura; Satoshi Ichiyama
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

3.  Molecular characterization of CTX-M β-lactamase and associated addiction systems in Escherichia coli circulating among cattle, farm workers, and the farm environment.

Authors:  Migma Dorji Tamang; Hyang-Mi Nam; Mamata Gurung; Geum-Chan Jang; Su-Ran Kim; Suk-Chan Jung; Yong Ho Park; Suk-Kyung Lim
Journal:  Appl Environ Microbiol       Date:  2013-04-12       Impact factor: 4.792

4.  Comparative study of genotype and virulence in CTX-M-producing and non-extended-spectrum-β-lactamase-producing Klebsiella pneumoniae isolates.

Authors:  Juyoun Shin; Kwan Soo Ko
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

5.  Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea.

Authors:  B Kim; J Kim; M-R Seo; S-H Wie; Y K Cho; S-K Lim; J S Lee; K T Kwon; H Lee; H J Cheong; D W Park; S Y Ryu; M-H Chung; M Ki; H Pai
Journal:  Infection       Date:  2013-03-16       Impact factor: 3.553

6.  Fitness cost associated with resistance to fluoroquinolones is diverse across clones of Klebsiella pneumoniae and may select for CTX-M-15 type extended-spectrum β-lactamase.

Authors:  A Tóth; B Kocsis; I Damjanova; K Kristóf; L Jánvári; J Pászti; R Csercsik; J Topf; D Szabó; P Hamar; K Nagy; M Füzi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-12-04       Impact factor: 3.267

7.  Molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli in the community and hospital in Korea: emergence of ST131 producing CTX-M-15.

Authors:  Sun Hee Park; Ji-Hyun Byun; Su-Mi Choi; Dong-Gun Lee; Si-Hyun Kim; Jae-Cheol Kwon; Chulmin Park; Jung-Hyun Choi; Jin-Hong Yoo
Journal:  BMC Infect Dis       Date:  2012-06-29       Impact factor: 3.090

8.  Diversity and biofilm-production ability among isolates of Escherichia coli phylogroup D belonging to ST69, ST393 and ST405 clonal groups.

Authors:  Ângela Novais; Claudia Vuotto; João Pires; Carolina Montenegro; Gianfranco Donelli; Teresa M Coque; Luísa Peixe
Journal:  BMC Microbiol       Date:  2013-06-21       Impact factor: 3.605

Review 9.  Current epidemiology and growing resistance of gram-negative pathogens.

Authors:  David M Livermore
Journal:  Korean J Intern Med       Date:  2012-05-31       Impact factor: 2.884

10.  The emergence of multidrug-resistant Klebsiella pneumoniae of international clones ST13, ST16, ST35, ST48 and ST101 in a teaching hospital in the Paris region.

Authors:  G Marcade; S Brisse; S Bialek; E Marcon; V Leflon-Guibout; V Passet; R Moreau; M-H Nicolas-Chanoine
Journal:  Epidemiol Infect       Date:  2012-10-04       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.